Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).
Share price
Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
Q1 2024 Run through
Watch as Nikolaj Sørensen, President and CEO, summarizes the quarter and Orexo's focus going forward.
Presentation of Q2 2024 - July 17 at 2 pm CET
Listen to the presentation where CEO Nikolaj Sørensen, and CFO Fredrik Järrsten, are presenting the latest development, which is followed by a Q&A.
Latest CEO Comments
JULY 17, 2024
"Strong Zubsolv® recovery and focus on getting OX124 to the US market"
Read the latest CEO comments from Nikolaj Sørensen
Annual General Meeting
Our shareholders were invited to attend the 2024 Annual General Meeting on April 26. Find out what decisions were taken and other information ahead of the AGM under the Corporate Governance section - AGM
Annual and Sustainability Report 2023
The Annual and Sustainability Report 2023 was published on March 28, at 8 am CET
ESG sustainability investing
Orexo has established a social financing framework
Key financial figures
Group net revenue
615.3 MSEK
Last Twelve Months, Q323-Q224
Group EBITDA
23.8 MSEK
Last Twelve Months, Q323-Q224
US Commercial segment EBIT
144.8 MSEK
Last Twelve Months, Q323-Q224
Cash position
139.7 MSEK
Q224
News flow
Press Releases and News
Orexo AB´s sustainability work ranked among top 5% by EcoVadis
Orexo: invitation to presentation of the Q2 2024 Interim Report
Orexo publishes prospectus and applies for admission to trading of social bonds on Nasdaq Stockholm
Fentanyl awareness day: The synthetic opioid fentanyl increasingly poisons young Americans
